AKBA Akebia Therapeutics, Inc.
Listings ·
Nasdaq says the stock closed below $1.00 for 30 consecutive business days. Cash fell from $184.8 million at year-end 2025 to $155.5 million at June 30, 2026, and the company says it could seek a reverse stock split.
Stockholders approved raising authorized common stock from 350,000,000 to 500,000,000 at a June 17, 2026 meeting, with 88,853,129 votes against. The 8-K does not say how many shares are outstanding or planned for issue.
Q32 Bio closed the asset sale on November 28, 2025 and is eligible for up to $580 million in milestones plus royalties. It now expects cash to fund operations into the second half of 2027.
Akebia priced 25,000,000 shares at $2.00 for gross proceeds of $50.0 million, below the $2.84 last sale price the final prospectus cites for March 19, 2025. The company estimates net proceeds of about $46.5 million and reports an accumulated deficit of $1,678,360 thousand.
Akebia drew the extended $10.0 million Tranche C loan on February 3, 2025, the last day of its extension. It received $9.3 million net and issued a warrant to a Kreos affiliate for 1,153,846 shares at $1.30 a share.
Akebia received net proceeds of $9.3 million on February 3, 2025. The warrant has an exercise price of $1.30 per share and runs eight years.
Akebia Therapeutics is a fully integrated biopharmaceutical company with two commercial products for patients with kidney disease. Its pipeline includes mid-stage programs for rare kidney diseases and early-stage programs for kidney disease and non-kidney indications. Its oral product Vafseo (vadadustat) was approved by the FDA in March 2024 for anemia due to chronic kidney disease (CKD) in adults on dialysis for at least three months, and it entered the U.S. market in January 2025. Auryxia (ferric citrate) is approved and marketed in the U.S. for serum phosphorus control in dialysis-dependent CKD and for iron deficiency anemia in non-dialysis-dependent CKD. The text says Auryxia reached loss of exclusivity in March 2025, and that Teva received tentative approval for its Abbreviated New Drug Application for Auryxia in January 2026. Mid-stage rare kidney disease assets include praliciguat, an oral soluble guanylate cyclase stimulator being evaluated in a Phase 2 trial for focal segmental glomerulosclerosis (FSGS), and AKB-097, a complement inhibitor acquired from Q32 Bio in November 2025. Early-stage assets include AKB-9090 and AKB-10108, which the text describes as HIF molecules. The text says CKD potentially affects approximately 35.5 million patients in the United States.
| Product or program | What it is | Stage |
|---|---|---|
| Vafseo | Oral treatment for anemia due to CKD in adults on dialysis | approved |
| Auryxia | Oral ferric citrate for phosphorus control and iron deficiency anemia in CKD | approved and marketed in the U.S. |
| praliciguat | Oral soluble guanylate cyclase stimulator for FSGS | Phase 2 |
| AKB-097 | Anti-C3d-Factor H fusion protein complement inhibitor for rare kidney diseases | clinical-stage |
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $62.4 million | $37.7 million |
| Net income (loss) | -$5.3 million | -$69.4 million |
| Cash from operations | $68.0 million | -$40.7 million |
| Cash and equivalents | $184.8 million | $51.9 million |
Our latest story on this, dated Oct 23, 2026: "Akebia Therapeutics gets Nasdaq bid price notice, has until April 19, 2027". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Mar 19, 2025: "Akebia launches stock offering, then prices 25,000,000 shares at $2.00 for $50.0 million". The story links the filing or release it is based on. Read the story.
Akebia Therapeutics, Inc. trades under the ticker AKBA on NASDAQ.
Akebia Therapeutics, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:AX9; LS:A1XF0S; LSX:A1XF0S.
The SEC Central Index Key (CIK) for Akebia Therapeutics, Inc. is 1517022. Its filings are on SEC EDGAR.
277,106,245 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-05.
Our directory records Akebia Therapeutics, Inc. under United States.
Our directory classifies Akebia Therapeutics, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Akebia Therapeutics, Inc. is US00972D1054.
aibio.space lists Akebia Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Akebia Therapeutics is a fully integrated biopharmaceutical company with two commercial products for patients with kidney disease. Its pipeline includes mid-stage programs for rare kidney diseases and early-stage programs for kidney disease and non-kidney indications.
Vafseo: Oral treatment for anemia due to CKD in adults on dialysis Stage: approved.
Auryxia: Oral ferric citrate for phosphorus control and iron deficiency anemia in CKD Stage: approved and marketed in the U.S..
Akebia Therapeutics, Inc. reported a net loss of $5.3 million for the fiscal year ended Dec 31, 2025, and generated $68.0 million of cash from operations, per its annual report to the SEC.
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Reported a financing. SEC Form 424B5. Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,2.03,3.02). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio